IN2014KN02324A - - Google Patents
Info
- Publication number
- IN2014KN02324A IN2014KN02324A IN2324KON2014A IN2014KN02324A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A IN 2324KON2014 A IN2324KON2014 A IN 2324KON2014A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A
- Authority
- IN
- India
- Prior art keywords
- masp
- inhibitory agent
- subject
- amount
- mas
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 abstract 13
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 abstract 9
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 5
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 3
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 abstract 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 abstract 2
- 230000024203 complement activation Effects 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 abstract 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621461P | 2012-04-06 | 2012-04-06 | |
| PCT/US2013/035488 WO2013180834A2 (en) | 2012-04-06 | 2013-04-05 | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02324A true IN2014KN02324A (ko) | 2015-05-01 |
Family
ID=49325295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2324KON2014 IN2014KN02324A (ko) | 2012-04-06 | 2013-04-05 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20130273053A1 (ko) |
| EP (2) | EP3366307B1 (ko) |
| JP (3) | JP6366571B2 (ko) |
| KR (2) | KR102142508B1 (ko) |
| CN (1) | CN104661676A (ko) |
| AU (3) | AU2013267909B2 (ko) |
| BR (1) | BR112014024793A2 (ko) |
| CA (2) | CA3087933A1 (ko) |
| CL (1) | CL2014002694A1 (ko) |
| CY (1) | CY1120736T1 (ko) |
| DK (2) | DK2833907T3 (ko) |
| ES (2) | ES2670668T3 (ko) |
| HK (1) | HK1206996A1 (ko) |
| HR (1) | HRP20180671T1 (ko) |
| HU (1) | HUE036930T2 (ko) |
| IL (2) | IL234991B (ko) |
| IN (1) | IN2014KN02324A (ko) |
| LT (1) | LT2833907T (ko) |
| MX (2) | MX357540B (ko) |
| NO (1) | NO2881536T3 (ko) |
| NZ (2) | NZ781091A (ko) |
| PL (2) | PL3366307T3 (ko) |
| PT (1) | PT2833907T (ko) |
| RS (1) | RS57266B1 (ko) |
| RU (2) | RU2018114903A (ko) |
| SI (1) | SI2833907T1 (ko) |
| TR (1) | TR201806939T4 (ko) |
| WO (1) | WO2013180834A2 (ko) |
| ZA (1) | ZA201408100B (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3131223C (en) * | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| EP3058951A1 (en) * | 2012-06-18 | 2016-08-24 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| CA2906096C (en) | 2013-03-15 | 2022-03-15 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| WO2018097307A1 (ja) * | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| TW202235438A (zh) | 2016-11-28 | 2022-09-16 | 日商中外製藥股份有限公司 | 能夠調節配體結合活性的配體結合分子 |
| US11827717B2 (en) | 2017-04-03 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Anti-MASP-1 antibodies and methods of use |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| BR112020024148A2 (pt) * | 2018-05-29 | 2021-03-30 | Omeros Corporation | Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2 |
| WO2019230867A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| MX2022001268A (es) * | 2019-07-31 | 2022-02-22 | Biocryst Pharm Inc | Regimenes de dosificacion para inhibidores orales del factor d del complemento. |
| WO2021113698A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CA3159176A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| RU2002113381A (ru) * | 1999-12-02 | 2004-01-27 | Дженс Христиан ДЖЕНСЕНИУС (DK) | MASP-3, комплемент-связывающий фермент и его применение |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7043719B2 (en) * | 2001-07-23 | 2006-05-09 | Intel Corporation | Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations |
| JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| EP1713929A2 (en) * | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1) |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2495257A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE419671T1 (de) * | 2006-07-31 | 2009-01-15 | Fiat Ricerche | Durch eine fluidströmung betätigbarer elektrischer generator |
| ES2628973T3 (es) | 2007-05-31 | 2017-08-04 | University Of Washington | Mutagénesis inducible de genes diana |
| EP2342231A1 (en) * | 2008-09-26 | 2011-07-13 | Roche Glycart AG | Bispecific anti-egfr/anti-igf-1r antibodies |
| AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| BRPI1010534A2 (pt) * | 2009-03-05 | 2016-03-15 | Smith & Nephew Inc | sistema, método e aparelho para colocação de um fio guia no colo femoral |
| KR101870378B1 (ko) * | 2009-07-17 | 2018-06-25 | 릭스하스피탈렛 | 보체 활성화의 억제제로서의 ｍａｓｐ 이소형 |
| EP2496259B1 (en) * | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria |
| CA3076975C (en) * | 2011-04-08 | 2024-06-18 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
-
2013
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
-
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
-
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
-
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
-
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
-
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02324A (ko) | ||
| MX2013011721A (es) | Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| IN2015DN01156A (ko) | ||
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| WO2010083239A3 (en) | Therapeutic modulation of vaginal epithelium boundary lubrication | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX367091B (es) | Una composición farmacéutica o cosmética tópica que comprende un extracto de la baya de la fruta milagrosa (synsepalum dulcificum) para usarse en el tratamiento o la prevención de desórdenes en la piel, mebrana mucosa, cabello, articulaciones y uñas. | |
| GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
| MX2015003074A (es) | Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas. | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| EA201491532A1 (ru) | Фармацевтические композиции для использования в комплексной терапии | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX2013014630A (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
| TN2015000048A1 (en) | Methods of administering rifaximin for weight loss and treatment of obesity | |
| WO2016108572A3 (ko) | 콜레스테롤 관련 질환의 예방 및 치료용 조성물 | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |